Palvella Therapeutics, Inc.
PVLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $25,902 | $31,418 |
| % Growth | – | -100% | -17.6% | – |
| Cost of Goods Sold | $0 | $0 | $2,780 | $2,368 |
| Gross Profit | $0 | $0 | $23,122 | $29,050 |
| % Margin | – | – | 89.3% | 92.5% |
| R&D Expenses | $8,151 | $8,793 | $50,212 | $64,197 |
| G&A Expenses | $5,944 | $3,076 | $0 | $0 |
| SG&A Expenses | $5,944 | $3,076 | $16,384 | $16,684 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,095 | $11,869 | $66,596 | $80,881 |
| Operating Income | -$14,095 | -$11,869 | -$43,474 | -$51,831 |
| % Margin | – | – | -167.8% | -165% |
| Other Income/Exp. Net | -$3,339 | $30,560 | $10,197 | $6,093 |
| Pre-Tax Income | -$17,434 | $18,691 | -$33,277 | -$45,738 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,434 | $18,691 | -$33,277 | -$45,738 |
| % Margin | – | – | -128.5% | -145.6% |
| EPS | -7.83 | 14.74 | -29.61 | -56.69 |
| % Growth | -153.1% | 149.8% | 47.8% | – |
| EPS Diluted | -7.83 | 14.74 | -29.61 | -56.69 |
| Weighted Avg Shares Out | 2,226 | 1,268 | 930 | 807 |
| Weighted Avg Shares Out Dil | 2,226 | 1,268 | 930 | 807 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $6,265 | $721 | $4 |
| Interest Expense | $4,317 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $2,780 | $2,368 |
| EBITDA | -$13,117 | $18,691 | -$30,497 | -$43,370 |
| % Margin | – | – | -117.7% | -138% |